GW Pharmaceuticals, Justin Gover: Occupying a world leading position in cannabinoid science




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: GW Pharmaceuticals, Justin Gover: Occupying a world leading position in cannabinoid science
Released on: April 30, 2014. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview, filmed at the BIA Conference, Fintan Walton talks to Justin Gover, CEO of GW Pharmaceuticals.
  • Summary
  • Transcript
  • Participants
  • Company
In this interview, filmed at the BIA Conference, Fintan Walton talks to Justin Gover, CEO of GW Pharmaceuticals. GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange,. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy
In this interview, filmed at the BIA Conference, Fintan Walton talks to Justin Gover, CEO of GW Pharmaceuticals. GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange,. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy
Justin Gover
GW Pharmaceuticals
GW Pharmaceuticals
GW Pharmaceuticals is a pharmaceutical firm developing a portfolio of cannabinoid medicines, of which the lead product is Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain and neuropathic pain.